Skip to main content
All lobbying filings

Mehlman Consulting, Inc.

Mehlman Consulting, Inc. filed a Q2 report for The Campaign for Sustainable RX Pricing on July 21, 2025, reporting $90,000 in lobbying income.

Lobbying for The Campaign for Sustainable RX Pricing · A coalition of organizations working on market-based solutions to drug pricing.

As filed: MEHLMAN CONSULTING, INC. for THE CAMPAIGN FOR SUSTAINABLE RX PRICING.

All filings by Mehlman Consulting, Inc. · Everything The Campaign for Sustainable RX Pricing has reported

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2025
Apr 1 - June 30 · Posted Jul 21, 2025
Income
$90,000
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Lobbyists on this filing 1
  • JON ADAME New on this filing
    Previously held: CoS, LD, GC (Sen. Blackburn); Counsel (Rep. Blackburn); Policy Coordinator (House E&C); Intern (Sen. Domenici)

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 3
Medicare/Medicaid

Prescription drug pricing issues. S. 229 Drug-price Transparency for Consumers (DTC) Act. H.R. 3789 - The Drug-price Transparency for Consumers (DTC) Act. H.R. 1 - One Big Beautiful Bill Act.

Pharmacy

Prescription drug pricing issues. H.R. 1843/S. 1302 - Increasing Transparency in Generic Drug Applications Act. S. 1954 - Biosimilar Red Tap Elimination Act.

Copyright/Patent/Trademark

Patent abuse issues. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.1096 - Preserve Access to Affordable Generics and Biosimilars Act. S.1095 - Stop STALLING Act. S. 1097 - Interagency Patent Coordination and Improvement Act of 2025. S. 43 - Skinny Labels, Big Savings Act. H.R. 3269/S. 2276 - ETHIC Act.

 Bills named in this filing 14
  • S. 229
    DTC Act of 2025
  • H.R. 3789
    DTC Act of 2025
  • H.R. 1
    One Big Beautiful Bill Act
  • H.R. 1843
    To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
  • S. 1302
    Increasing Transparency in Generic Drug Applications Act
  • S. 1954
    Biosimilar Red Tape Elimination Act
  • S. 1040
    Drug Competition Enhancement Act
  • S. 1041
    Affordable Prescriptions for Patients Act
  • S. 1096
    Preserve Access to Affordable Generics and Biosimilars Act
  • S. 1095
    Stop STALLING Act
  • S. 1097
    Interagency Patent Coordination and Improvement Act of 2025
  • S. 43
    Skinny Labels, Big Savings Act
  • H.R. 3269
    ETHIC Act
  • S. 2276
    ETHIC Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem